Sexa | Female n = 52/81 (64.2%) | Male n = 28/81 (34.6%) | All n = 81 (100.0%) |
---|---|---|---|
Age in years at the time of testing | |||
Mean (SD) | 43.3 years (SD = 3.8) | 46.1 years (SD = 6.9) | 44.0 years (SD = 3.4) |
≤ 14 | 0 | 1 (3.6%) | 1 (1.2%) |
15–49 | 35 (67.3%) | 16 (57.1%) | 51 (63.0%) |
≥ 50 | 17 (32.7%) | 11 (39.3%) | 28 (34.6%) |
NA | 0 | 0 | 1 (1.2%) |
Nationality | Available on n = 26/52 (50.0%) | Available on n = 9/28 (32.1%) | Available on n = 35/81 (43.2%) |
Bolivia | 13 (50.0%) | 7 (77.8%) | 20 (57.1%) |
Germany | 0 | 2 (22.2%) | 2 (5.7%) |
Brazil | 5 (19.2%) | 0 | 5 (14.3%) |
Paraguay | 2 (7.7%) | 0 | 2 (5.7%) |
Argentina | 3 (11.5%) | 0 | 3 (8.6%) |
Peru | 2 (7.7%) | 0 | 2 (5.7%) |
South America | 1 (3.8%) | 0 | 1 (2.9%) |
Reason for testing | Available on n = 33/52 (63.5%) | Available on n = 12/28 (42.9%) | Available on n = 45/81 (55.6%) |
Known CD | 17 (51.5%) | 7 (58.3%) | 24 (53.3%) |
Endemic national | 7 (21.2%) | 2 (16.7%) | 9 (20.0%) |
Other | 9 (27.3%) | 3 (25.0%) | 12 (26.7%) |
Symptoms | Available on n = 23/52 (44.2%) | Available on n = 9/28 (32.1%) | Available on n = 32/81 (39.5%) |
Fatigue | 0 | 2 (22.2%) | 2 (6.3%) |
Gastrointestinal | 9 (39.1%) | 2 (22.2%) | 11 (34.4%) |
Cardiac | 3 (13.0%) | 0 | 3 (9.4%) |
Other | 1 (4.3%) | 2 (22.2%) | 3 (9.4%) |
No symptoms | 10 (43.5%) | 3 (33.3%) | 13 (40.6%) |
Initial diagnosis of CD | Available on n = 30/52 (57.7%) | Available on n = 13/28 (46.4%) | Available on n = 43/81 (53.1%) |
Yes | 10 (33.3%) | 5 (38.5%) | 15 (34.9%) |
No | 20 (66.7%) | 8 (61.5%) | 28 (65.1%) |
Echocardiography | Available on n = 18/52 (34.6%) | Available on n = 5/28 (17.9%) | Available on n = 23/81 (28.4%) |
Normal | 16 (88.9%) | 3 (60.0%) | 19 (82.6%) |
Abnormal | 0 | 1 (20.0%) | 1 (4.3%) |
Not performed | 2 (11.1%) | 1 (20.0%) | 3 (13.0%) |
Electrocardiography | Available on n = 18/52 (34.6%) | Available on n = 9/28 (32.1%) | Available on n = 27/81 (33.3%) |
Normal | 16 (88.9%) | 6 (66.7%) | 22 (81.5%) |
Abnormal | 2 (11.1%) | 2 (22.2%) | 4 (14.8%) |
Not performed | 0 | 1 (11.1%) | 1 (3.7%) |
Etiologic treatment | Available on n = 22/52 (42.3%) | Available on n = 7/28 (25.0%) | Available on n = 29/81 (35.8%) |
Benznidazole | 8 (36.4%) | 3 (42.9%) | 11 (37.9%) |
Nifurtimox | 2 (9.1%) | 0 | 2 (6.9%) |
No treatment | 12 (54.5%) | 4 (57.1%) | 16 (55.2%) |
Treatment course | Available on n = 8/10 (80.0%) | Available on n = 1/3 treatments (33.3%) | Available on n = 9/13 treatments (69.2%) |
Completed treatment | 5 (62.5%) | 0 | 5 (55.6%) |
Stopped treatment | 3 (37.5%) | 1 (100%) | 4 (44.4%) |
Side effects | Available on n = 3/10 treatments (30.0%) | Available on n = 1/3 treatments (33.3%) | Available on n = 4/13 treatments (30.8%) |
Yes | 3 (100%) | 1 (100%) | 4 (100%) |
No | 0 | 0 | 0 |
Reason for no treatment | Available on n = 11/12 (91.7%) | Available on n = 4/4 (100%) | Available on n = 15/16 (93.8%) |
Recommendations-based reason | 5 (45.5%) | 2 (50.0%) | 7 (46.7%) |
Non-recommendations-based reason | 6 (54.5%) | 2 (50.0%) | 8 (53.3%) |
Follow-up | Available on n = 13/52 (25.0%) | Available on n = 4/28 (14.3%) | Available on n = 17/81 (21.0%) |
> 12 months | 7 (53.8%) | 3 (75.0%) | 10 (58.8%) |
≤ 12 months | 4 (30.8%) | 1 (25.0%) | 5 (29.4%) |
No follow-up | 2 (15.4%) | 0 | 2 (11.8%) |